Evaluation of the Efficacy of Non-drug Therapy (SMS Intervention) for Adolescents With NSSI
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Department of Psychiatry, Xiangya Second Hospital, Central South University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adolescents aged 10-19 years old.
- Meet the diagnostic criteria of NSSI behavior recommended by DSM-5.
- The adolescents who have mobile phone, and have the ability to send or receive text messages.
- Adolescents and guardians agreed to participate and signed the informed consent form
Exclusion Criteria:
- Adolescents with severe somatic diseases who cannot complete the study.
- Adolescents with cognitive impairment, neurodevelopmental disorder, mental retardation, visual impairment who cannot complete the study.
- The adolescents who do not have a mobile phone.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
OTHER: intervention group
Text messages will be sent to the subjects through the investigator, including giving popularization of psychiatric knowledge, coping skills, emotional regulation strategies, and brief care.
Two or three times a week for two months.
|
SMS intervention
|
|
NO_INTERVENTION: control group
Subjects both collected in the outpatient department and the ward were randomly divided into the control group and regularly followed up.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of NSSI behavior of the participants.
Time Frame: At baseline, the fourth week, the eighth week
|
NSSI behavior will be measured by Nonsuicidal self-injury Questionnaire which contains several items designed by investigators.
The questionnaire is mainly used to measure the frequency of NSSI among adolescents.
|
At baseline, the fourth week, the eighth week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of anxiety level.
Time Frame: At baseline, the fourth week, the eighth week
|
The Generalized Anxiety Disorder 7-item Scale will be used to measure the change of anxiety.
GAD-7 scale consists of 7 items.
Each item ranging from 0 to 3, and the total score ranging from 0 to 21.
The higher score indicates severe anxiety symptoms.
|
At baseline, the fourth week, the eighth week
|
|
The change of depression level.
Time Frame: At baseline, the fourth week, the eighth week
|
The Patient Health Questionnaire 9-item will be used to measure the change of depression.
PHQ-9 scale consists of 9 items.
Each item raging from 0 to 3, and the total score ranging from 0 to 27.
The higher score indicates severe depression symptoms.
|
At baseline, the fourth week, the eighth week
|
|
The change of hopelessness.
Time Frame: At baseline, the fourth week, the eighth week
|
The Beck Hopelessness Scale will be used to measure the change of hopelessness.
BHS scale consists of 20 items.
Each item can be answered "yes" or "no" for 1 or 0 points respectively.
The total score ranging from 0 to 20.
A higher total score indicates a higher degree of hopelessness.
|
At baseline, the fourth week, the eighth week
|
|
The change of emotion regulation strategies.
Time Frame: At baseline, the fourth week, the eighth week
|
The Emotion Regulation Questionnaire will be used to measure the change of emotion regulation styles.
ERQ scale consists of 10 items which can be divided into cognitive reappraisal and expression suppression two emotion-regulating strategy subscales.
Each item ranging from 1 to 7 points.
The higher the score, the more often the respondent used this emotion-regulating strategy.
|
At baseline, the fourth week, the eighth week
|
|
The change of coping styles.
Time Frame: At baseline, the fourth week, the eighth week
|
The Simplified Coping Style Questionnaire will be used to measure the change of coping styles.
SCSQ scale consists of 20 items which can be divide into positive coping styles and negative coping styles in two dimensions.
Each item raging from 0 to 3, and the total score ranging from 0 to 60.
The higher the score, the more likely the respondents are to use this coping style.
|
At baseline, the fourth week, the eighth week
|
|
The change of life events stress.
Time Frame: At baseline, the fourth week, the eighth week
|
The Adolescent Self-Rating Life Events Check-list will be used to measure the frequency and intensity of life events that may trigger a stressful psychological response in adolescents.
There are 27 items in the scale, which can be divided into 6 dimensions.
The scale scores ranged from 27 to 135.
The higher the score means the higher the degree of negative life event stress.
The scale is widely used in China and has good reliability and validity.
|
At baseline, the fourth week, the eighth week
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MD20200309
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.